Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU

RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue to persist despite advancements in treatment,” said Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Janssen Research & Development, LLC. “At this year’s meeting, we look forward to highlighting results from our GU portfolio and pipeline, including a new analysis of time to second progression or death after initial treatment with ERLEADA from the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer; and new data for BALVERSA in combination with an anti-PD-1 monoclonal antibody.”Highlights from the Janssen oncology portfolio and pipeline will include: New Analyses from the Phase 3 TITAN Study of ERLEADA® in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)An oral presentation will feature a post-hoc analysis of data from the Phase 3 TITAN study on the time to second progr...

Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news